Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus METI DERM.
COR-OTICIN vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid